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Upregulation of Nitric Oxide Production in Vascular
Endothelial Cells by All-trans Retinoic Acid Through the
Phosphoinositide 3-Kinase/Akt Pathway
Akira Uruno, MD, PhD; Akira Sugawara, MD, PhD; Hiroshi Kanatsuka, MD, PhD;
Hiroyuki Kagechika, PhD; Akiko Saito, MD; Kazunori Sato, MD, PhD; Masataka Kudo, MD, PhD;
Kazuhisa Takeuchi, MD, PhD; Sadayoshi Ito, MD, PhD
Background—A natural retinoid all-trans retinoic acid (ATRA) contains various beneficial effects on vasculature,
including suppression of neointima formation after balloon injury. However, little is known about the effects of ATRA
on vascular endothelial function. We therefore studied its role in nitric oxide (NO) production of vascular endothelial
cells (ECs).
Methods and Results—Human dermal microvascular ECs, human umbilical vein ECs, and SV40-transformed rat lung
vascular ECs were incubated with or without ATRA (1 mol/L) for 48 hours. Their NO production was determined with
the use of a fluorescent NO indicator, diaminofluorescein-2 diacetate. ATRA significantly increased their basal as well
as acetylcholine-induced NO production. Treatment with N-nitro-L-arginine methyl ester or carboxy-PTIO suppressed
their fluorescence. Increase of NO production was also observed by incubation with retinoic acid receptor (RAR) agonist
Am580. ATRA-induced NO increase was abolished by coincubation with RAR antagonist LE540. Moreover, the NO
increase was completely inhibited by the phosphoinositide 3-kinase (PI3K) inhibitor wortmannin and LY294002. ATRA
as well as Am580 enhanced endothelial NO synthase (eNOS) phosphorylation at Ser-1177 as well as Akt
phosphorylation at Ser-473 without changing their protein expression. Overexpression of dominant-negative Akt
inhibited the eNOS phosphorylation. Moreover, ATRA increased PI3K activity as well as PI3K catalytic subunit p110
protein expression, which was completely inhibited by LE540 treatment. Real-time polymerase chain reaction analyses
demonstrated that ATRA increased PI3K catalytic subunit p110 mRNA expression without affecting its stability.
Finally, ATRA-induced NO increase was observed in COS-1 cells transfected with wild-type eNOS and RAR, but not
with mutated eNOS whose Ser-1177 was substituted.
Conclusions—ATRA increases NO production by eNOS phosphorylation through RAR-mediated PI3K/Akt pathway
activation in vascular ECs and possibly plays beneficial roles in vascular endothelium. Retinoids may therefore be
candidates as novel therapeutic agents against vascular disorders with endothelial damage. (Circulation. 2005;112:727-
736.)
Key Words: endothelium  nitric oxide  receptors
All-trans retinoic acid (ATRA), a natural retinoid derivedfrom vitamin A, has recently been reported to induce
differentiation and inhibit proliferation, cell migration, in-
flammation, and extracellular matrix synthesis of vascular
smooth muscle cells (VSMCs).1–4 Moreover, ATRA is re-
ported to suppress neointima formation and restenosis after
balloon injury in vivo.5,6 In vascular endothelium, ATRA as
well as other retinoids is reported to modulate endothelial cell
growth and phenotype7,8; to induce antithrombotic genes
including urokinase-type plasminogen activator,9 tissue-type
plasminogen activator,10 and thrombomodulin11; and to im-
prove acetylcholine (ACh)-induced relaxation in rat aorta.12
ATRA is thus considered to have favorable effects not only in
VSMCs but also in vascular endothelium. However, roles of
ATRA in endothelium still remain unclear.
Nitric oxide (NO) is a potent vasodilator and signal
modulator molecule, and endothelium-derived NO in partic-
ular plays important roles in controlling vascular function,
including suppression of vascular remodeling.13,14 With re-
gard to the effects of ATRA on NO synthesis in endothelium,
although a previous study has demonstrated its increase by
ATRA through alteration of the metabolism of endogenous
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NO synthase (NOS) inhibitor asymmetric dimethylarginine
(ADMA),15 little is known about the effects of ATRA on
endothelium-derived NO production with regard to endothe-
lial NOS (eNOS) function. We therefore examined the effects
of ATRA on NO production as well as eNOS phosphoryla-
tion regulation in vascular endothelial cells (ECs).
Methods
Reagents
ATRA, wortmannin, LY294002, N-nitro-L-arginine methyl ester
(L-NAME), and ACh were purchased from Sigma-Aldrich. The
synthetic retinoic acid receptor (RAR) agonist Am580, RAR antag-
onist LE540, and retinoid X receptor (RXR) antagonist HX603 were
synthesized as previously described.16–18 Diaminofluorescein-2 di-
acetate (DAF-2DA) was purchased from Daiichi Pure Chemicals.
Carboxy-PTIO was purchased from Dojindo.
Cell Culture
Vascular ECs were cultured on a monolayer plastic dish in a
humidified incubator at 37°C with 5% CO2. Human dermal micro-
vascular ECs (HMVECs) were purchased from Kurabo and cultured
in HuMedia-EB2 (Kurabo) supplemented with 5% fetal bovine
serum (FBS), 10 ng/mL human epidermal growth factor (hEGF), 5
ng/mL human basic fibroblast growth factor, 1 g/mL hydrocorti-
sone, 10 g/mL heparin, 39.3 g/mL dibutyryl-cAMP, 50 g/mL
gentamicin, and 50 ng/mL amphotericin-B. HMVECs were used
between passages 5 and 6. Human umbilical vein ECs (HUVECs)
were purchased from Clonetics and were cultured in endothelial cell
basal medium (Clonetics) supplemented with 2% FBS, 10 ng/mL
hEGF, 1 g/mL hydrocortisone, 12 g/mL bovine brain extract, 50
g/mL gentamicin, and 50 ng/mL amphotericin-B. HUVECs were
used between passages 1 and 4. SV40-transformed rat lung vascular
endothelial cell line (TRLEC-03)19 was cultured in RPMI-1640
supplemented with 5% FBS, 100 g/mL streptomycin, and 100
g/mL penicillin.
Measurement of NO Production in ECs
NO production in cultured ECs was studied with the use of
DAF-2DA as a fluorescent indicator for intracellular NO. When ECs
cultured on a microcoverglass (Matsunami Glass) in 100-mm culture
dish were grown to 50% confluence, they were replaced with media
containing 1% resin and charcoal-treated FBS (stripped FBS).20
ATRA and/or other retinoid was then added to the media, and cells
were incubated for indicated times. ECs adherent to the microcov-
erglass were fixed to a homeothermal chamber, and perfusions were
thereafter performed at 37°C with physiological salt solution (PSS)
(in mmol/L: 145 NaCl, 4.7 KCl, 2 CaCl2, 1.17 MgSO4, 1.2 NaH2PO4,
2 pyruvate, 0.02 EDTA, 3 MOPS, 5 glucose, pH 7.40). Cells were
loaded with 15 mol/L DAF-2DA for 30 minutes and were then
washed with PSS for 15 minutes. DAF-2DA permeates cell mem-
brane and converts to DAF-2,21 which reacts with NO and changes
to a triazole form (DAF-2T) that yields high fluorescence.22 NO
production was determined by measurement of DAF-2T fluorescent
intensity as follows. Microscopes and fluorescent imaging systems
used were previously described.23,24 Briefly, fluorescent NO images
were obtained from microscope (model ECLIPSE E600, Nikon)
equipped with 20 (for HMVECs) or 60 (for TRLEC-03) objec-
tive. Excitation light was passed though a 495-nm filter, and emitted
light was passed through a 510-nm filter. Fluorescent images of NO
were enhanced with an image intensifier (C3100, Hamamatsu
Photonics) and recorded by a high-speed video system (MHS-200,
Nac), and fluorescent intensity analysis was performed on a Macin-
tosh computer with the use of the public domain NIH Image program
(developed at US National Institutes of Health and available on the
Internet at http://rsb.info.nih.gov/nih-image/). In some experiments,
ACh (10 mol/L) was added to PSS for 10 minutes after the
washout. ACh responsiveness was determined by increment of
DAF-2T fluorescence per minute after ACh stimulation for 10
minutes (dFl/dt).
RNA Preparation/Reverse Transcription–
Polymerase Chain Reaction
Total RNAs of HUVECs and TRLEC-03 were extracted with the use
of RNeasy mini kit (Qiagen) according to the manufacturer’s
instructions. The extracted RNAs (0.5 g) were then subjected to
reverse transcription (RT)–polymerase chain reaction (PCR) by
RNA PCR Kit (AMV) version 3.0 (Takara Bio) with the use of
specific primers for either M3 muscarinic ACh receptor or glycer-
aldehyde-3-phosphate-dehydrogenase (GAPDH). RT-PCR for hu-
man M3 receptor (forward primer: 5-AAG-TCA-GAT-CAC-TAA-
GCG-GA-3 [from position 1416 to 1435 in human M3 receptor
cDNA {GenBank accession number AF498917}]; reverse primer:
5-GCC-AGT-AGC-CCA-GAT-TCC-AA-3 [from position 1575 to
1594 in the cDNA]) (PCR product: 179 bp) was performed under the
following conditions: 50°C, 30 minutes and 99°C, 5 minutes for RT
with the use of oligo(dT)-adaptor primer; 94°C, 2 minutes for 1
cycle; 94°C, 1 minute; 46°C, 1 minute; 72°C, 1 minute for 37 cycles.
RT-PCR for human GAPDH (forward primer: 5-CCA-TGG-AGA-
AGG-CTG-GGG-3; reverse primer: 5-CAA-AGT-TGT-CAT-
GGA-TGA-CC-3)25 (PCR product: 195 bp) was performed under
the following conditions: 37°C, 10 minutes; 42°C, 30 minutes; and
99°C, 5 minutes for RT with the use of random 9-mer; 94°C, 2
minutes for 1 cycle; 94°C, 1 minute; 55°C, 1 minute; 72°C, 1 minute
for 35 cycles. RT-PCR for rat M3 receptor (forward primer:
5-AGG-TTT-GCT-CTC-AAG-ACC-AG-3 [from position 1393 to
1402 in rat M3 receptor cDNA {GenBank accession number
M16408}]; reverse primer: 5-CAC-AAG-AGG-AGC-GTC-TTG-
AA-3 [from position 1660 to 1679 in the cDNA]) (PCR product:
287 bp) and rat GAPDH (forward primer: 5-TCC-CTC-AAG-ATT-
GTC-AGC-AA-3; reverse primer: 5-AGA-TCC-ACA-ACG-GAT-
ACA-TT-3)25 (PCR product: 308 bp) was performed under the
following conditions: 37°C, 10 minutes; 42°C, 30 minutes; and
99°C, 5 minutes for RT with the use of random 9-mer; 94°C, 2
minutes for 1 cycle; 94°C, 1 minute; 56°C, 1 minute; 72°C, 1 minute
for 40 cycles. The RT-PCR products were thereafter subjected to
electrophoresis on 1.5% agarose gel.
Real-Time PCR
TRLEC-03 grown to 80% confluence was incubated either with or
without ATRA (1 mol/L) for 48 hours, and total RNAs were
harvested as described above. For determination of mRNA stability,
TRLEC-03 incubated either with or without ATRA for 48 hours was
coincubated with 5 g/mL actinomycin D (Nacalai Tesque) for an
additional 3 or 6 hours before harvesting. Real-time PCR analyses of
rat phosphoinositide 3-kinase (PI3K) catalytic subunit p110 and rat
GAPDH were then performed with the use of the obtained total
RNAs by SYBR RT-PCR Kit (Perfect Real Time) (Takara Bio)
according to the manufacturer’s instructions. Briefly, RT reaction
(42°C, 15 minutes and 95°C, 2 minutes) was performed with 600 ng
total RNAs by random 6-mer. Thereafter, obtained templates (40 ng)
were used for real-time PCR reactions (95°C, 10 seconds for 1 cycle;
95°C, 5 seconds; and 60°C, 20 seconds for 45 cycles) with the use of
SYBR Green I by Smart Cycler (Cephied). Standard curves were
obtained by real-time PCR with the use of serial dilutions of
templates (40 ng, 10 ng, 4 ng, 1 ng, 400 pg, and 100 pg), and
threshold cycle values were calculated.
The following primer sequences were used: rat PI3K catalytic
subunit p110 (forward primer: 5-CAG-TGG-AGA-CAG-TGC-
GAA-CGT-A-3 [from position 1557 to 1578 in rat PI3K catalytic
subunit p110 cDNA {GenBank accession number NM053481}];
reverse primer: 5-TCG-GCA-GTC-TTG-CCG-TAG-AG-3 [from
position 1679 to 1698 in the cDNA]) (PCR product: 142 bp), rat
GAPDH (forward primer: 5-GAC-AAC-TTT-GGC-ATC-GTG-
GA-3 [from position 1339 to 1358 in rat GAPDH cDNA {GenBank
accession number NM017008}]; reverse primer: 5-ATG-CAG-
GGA-TGA-TGT-TCT-GG-3 [from position 1452 to 1471 in the
cDNA]) (PCR product: 133 bp).
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Protein Preparation/Western Blotting
HMVECs were cultured in a 6-well dish, and TRLEC-03 was
cultured in a 100-mm dish. When cells were grown to 80%
confluence, they were replaced with media containing 1% stripped
FBS.20 Cells were then incubated with or without ATRA and/or
other retinoid for indicated times. Total cellular extracts were
prepared as follows. Cells were washed with cold phosphate buffered
saline (PBS) 3 times, then 100 L (for HMVECs) or 300 L (for
TRLEC-03) of cell lysis buffer (in mmol/L: 100 NaCl, 20 Tris-HCl,
pH 7.40, 2.5 EDTA, 10 NaF, 1 Na3VO4, 1% Triton X-100, 1%
sodium deoxycholate, 0.1% SDS, protease inhibitor cocktail [Com-
plete Mini, Rosh]) was added. The mixtures were homogenized with
Polytron homogenizer for 30 seconds, and cell debris was removed
by centrifugation at 14 000g for 10 minutes. For Western blotting of
eNOS and Akt of HMVECs and Akt and PI3K catalytic subunit
p110 of TRLEC-03, their crude proteins (30 g for HMVECs and
100 g for TRLEC-03) were added to 2 SDS sample buffer
(125 mmol/L Tris-HCl, pH 6.80, 4% SDS, 20% glycerol,
100 mmol/L dithiothreitol, 0.02% bromophenol blue) and boiled at
95°C for 5 minutes. For Western blotting of eNOS of TRLEC-03, its
crude extracts (500 g) were added to 75% 25 ADP Sepharose 4B
(Amersham Biosciences) and were rotated at 4°C for 3 hours. The
beads were washed with cell lysis buffer 3 times, and the bound
proteins were eluted in 60 L of 1 SDS sample buffer
(62.5 mmol/L Tris-HCl, pH 6.80, 2% SDS, 10% glycerol,
50 mmol/L dithiothreitol, 0.01% bromophenol blue) at 95°C for 5
minutes. Nuclear extracts of TRLEC-03 for Western blotting of RAR
and RXR were prepared as previously described.26
Samples were separated on a 7.5% or a 9.0% SDS-polyacrylamide
gel and were transferred onto PVDF membrane (Bio-Rad). The
membranes were blocked with 5% nonfat dry milk and thereafter
probed with primary antibody against either eNOS (1:1000 dilution)
(Sigma); phospho-eNOS (Ser-1177) (1:400 dilution) (Cell Signaling
Technology); Akt (1:1000 dilution) (Cell Signaling Technology);
phospho-Akt (Ser-473) (1:500 dilution) (Cell Signaling Technol-
ogy); PI3K catalytic subunit p110 (1:1000 dilution) (Santa Cruz);
RAR, ,  (all 1:400 dilution) (Santa Cruz); or RXR, ,  (all
1:200 dilution).26 In an experiment, primary antibody against induc-
ible NOS (iNOS) (1:300 dilution) (Santa Cruz) was also used.
Horseradish peroxidase–linked antibodies (Amersham Biosciences)
were then used as secondary antibodies. Blotted membranes were
visualized with ECL-plus reagent (Amersham Biosciences) and
lumino-image analyzer LAS-1000 (Fuji Film).
Measurement of PI3K Activity
PI3K activity was measured by enzyme-linked immunosorbent assay
(ELISA). When TRLEC-03 cultured in 100-mm dish was grown to
80% confluence, it was replaced with media containing 1% stripped
FBS.20 Cells were thereafter incubated with or without ATRA for
indicated times. They were then washed 3 times with cold buffer A
(in mmol/L: 137 NaCl, 20 Tris-HCl, pH 7.4, 1 CaCl2, 1 MgCl2, 0.1
Na3VO4) and were lysed with 1 mL lysis buffer (buffer A with 1%
NP-40 and 1 mmol/L phenylmethylsulfonyl fluoride). Cell debris
was removed by centrifugation at 14 000g for 10 minutes. Five
microliters of anti-PI3K regulatory subunit p85 antibody (Upstate)
was added to the lysates, and they were rotated at 4°C for 1 hour.
Sixty microliters of 50% protein A Sepharose (Amersham Bio-
sciences Corp) was thereafter added to the mixtures, and they were
rotated at 4°C for another hour. The beads were washed 3 times with
wash buffer (buffer A with 1% NP-40), then 3 times with TNE buffer
(in mmol/L: 10 Tris-HCl, pH 7.4, 150 NaCl, 5 EDTA, 0.1 Na3VO4).
Immunoprecipitated proteins were incubated with PI(4,5)P2 sub-
strates in vitro, and PI(3,4,5)P3 products were measured with the use
of PI3-kinase ELISA kit (Echelon Biosciences) according to the
manufacturer’s instructions.
Transient Transfection Studies
Human full-length wild-type eNOS cDNA (3.6 kb) was isolated by
RT-PCR from HMVEC total RNAs with the use of specific primers
(forward: 5-CCCAAGCTTACCATGGGCAACTTGAAGAG-
CCTG-3; reverse: 5-GGAATTCAGGGGCTGTTGGTGTCTGA-
3). The isolated cDNA was confirmed to be identical to the
previously reported clone (NM_000603) by sequencing and was
subcloned into pcDNA3.1 expression vector (Invitrogen) (pcDNA3/
wt-eNOS). The wild-type eNOS cDNA was then subjected to
PCR-based site-directed mutagenesis to substitute Ser-1177 to Ala
(pcDNA3/mut-eNOS). COS-1 cells grown on a microcoverglass
(Matsunami Glass) in a 100-mm culture dish were transfected with
4 g of human RAR cDNA expression vector (pSG5hRAR) and
16 g of pcDNA3/wt-eNOS or pcDNA3/mut-eNOS with the use of
Lipofectamine 2000 (Invitrogen) according to the manufacturer’s
instructions. After transfection, cells were incubated with or without
ATRA (1 mol/L) for 48 hours. Cells were then subjected to
measurement of NO production with the use of DAF-2DA as
described above in vascular ECs.
In some experiments, TRLEC-03 grown in a 100-mm dish was
transfected with 10 g of pcDNA3/wt-eNOS and 10 g of wild-type
Akt cDNA expression vector [Akt1 (wt) in pUSEamp(), Upstate]
or dominant-negative Akt cDNA expression vector [Akt1 (K179M)
in pUSEamp(), Upstate] with the use of Lipofectamine 2000
(Invitrogen). Cells were then incubated with or without ATRA (1
mol/L) for 48 hours. Their total cellular extracts were then prepared
and were subjected to Western blotting as described above.
Statistical Analyses
All data are presented as meanSEM. Statistical analyses were
performed with ANOVA followed by post hoc Tukey test.
Results
Effects of ATRA on NO Production in Vascular ECs
Effects of ATRA on NO production were first examined. ATRA
treatment (1 mol/L, 48 hours) significantly increased NO produc-
tion in HMVECs [Figure 1A and 1B; 1734.0% of ATRA()],
HUVECs [Figure 1A and 1B; 25914% of ATRA()], and
TRLEC-03 [Figure 1A and 1B; 17319% of ATRA()]. RAR
agonist Am580 also increased NO production in HMVECs [Figure
1C; 1665.7% of Am580()] and HUVECs [Figure 1C;
23718% of Am580()]. ACh-induced NO release was also
significantly enhanced by ATRA in both HUVECs [Figure 1D and
1E; 18731% of ATRA()] and TRLEC-03 [Figure 1D and 1E;
15921% of ATRA()]. Expression of M3 muscarinic ACh
receptor, functioning predominantly in vasculature,27 was con-
firmed both in HUVECs (Figure 1F, lane 2) and TRLEC-03 (Figure
1F, lane 7).
ATRA increased NO production in a concentration-dependent
manner (Figure 2A; 15722% of 0 mol/L at 107 mol/L and
18310% of 0 mol/L at 106 mol/L). Time course analyses (Figure
2B) demonstrated that ATRA increased NO production later than
48 (17118% of 0 hour) and 96 (1629.1% of 0 hour) hours, but
not by 24 hours (10411% of 0 hour).
Effects of NO Scavenger and NOS Inhibitor on
NO Increase
To confirm whether the DAF-2T fluorescence increase was
specifically derived from NO increase, effects of specific NO
scavenger carboxy-PTIO28 were examined. In the presence of
carboxy-PTIO, both basal [ATRA()] (Figure 3A and 3B,
lane 2) and ATRA-induced [ATRA()] (Figure 3A and 3B,
lane 5) DAF-2 fluorescence was completely suppressed. We
next examined the effects of the NOS inhibitor L-NAME to
determine whether the NO increase was obtained from NOS-
derived de novo synthesis. Treatment with L-NAME diminished
basal [ATRA()] NO level (Figure 3A and 3B, lane 3,
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253.8% of lane 1) as well as ATRA-induced [ATRA()] NO
increase (Figure 3A and 3B, lane 6, 202.4% of lane 4).
Involvement of Retinoid Receptors in NO Increase
We examined involvement of retinoid receptors in the ATRA-
induced NO increase. Western blotting revealed that TRLEC-03
expressed RAR, RAR (Figure 4A), and RXR (Figure 4B).
Effects of selective RAR and/or RXR antagonists were next
examined (Figure 4C). ATRA-induced NO production (lane 2,
18014% of lane 1) was suppressed by cotreatment with RAR
antagonist LE540 (lane 3, 12412% of lane 1), whereas RXR
antagonist HX603 showed little effect (lane 4, 17620% of lane
1). Cotreatment with both LE540 and HX603 did not show
further suppression compared with LE540 alone (lane 5,
10914% of lane 1). These data suggest that RAR, rather than
RXR, is involved in the NO increase.
Effects of PI3K Inhibitor on NO Increase
Because several reports demonstrated involvement of PI3K in
NO increase after various stimuli, including vascular endo-
Figure 1. Effects of ATRA on NO production in ECs. A, Basal NO production visualized with DAF-2 DA. HMVECs, HUVECs, or
TRLEC-03 was incubated with [ATRA()] or without [ATRA()] ATRA (1 mol/L) for 48 hours, and NO production was determined by
DAF-2T fluorescence (B). C, Effects of Am580 on NO production in ECs. HMVECs or HUVECs were incubated with [Am580()] or with-
out [Am580()] Am580 (1 mol/L) for 48 hours, and NO production was determined by DAF-2T fluorescence. D, ACh-stimulated NO
production visualized with DAF-2 DA. HUVECs or TRLEC-03 was incubated with [ATRA()] or without [ATRA()] ATRA (1 mol/L) for
48 hours, and cells were thereafter stimulated with ACh (10 mol/L). ACh responsiveness was determined by increment of DAF-2T flu-
orescence per minute after 10-minute ACh stimulation (dFl/dt) (E). F, Expression of M3 muscarinic ACh receptor in HUVECs and
TRLEC-03. Lanes 1 and 6, 100-bp DNA ladder; lane 2, human M3 receptor; lane 3, human GAPDH; lane 4, human M3 receptor without
RT; lane 5, human GAPDH without RT; lane 7, rat M3 receptor; lane 8, rat GAPDH; lane 9, rat M3 receptor without RT; lane 10, rat
GAPDH without RT. Results in B, C, and E represent meanSEM of 3 independent experiments (n18). In B, C, and E, *P0.01 vs
ATRA() or Am580().
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thelial growth factor29 and estradiol,30 we next examined the
effects of the PI3K inhibitor wortmannin and LY294002
(Figure 4D). ATRA-induced NO increase (lane 2, 1596.9%
of lane 1) was completely abrogated by treatment with
wortmannin (30 nmol/L) (lane 4, 754.8% of lane 1) or
LY294002 (lane 5, 9916% of lane 1), suggesting involve-
ment of PI3K in the NO increase.
Effects of ATRA on eNOS Phosphorylation
at Ser-1177
To examine involvement of eNOS in the NO increase,
Western blotting with the use of antibody against phospho-
eNOS (Ser-1177) or eNOS was performed. ATRA signifi-
cantly increased eNOS phosphorylation at Ser-1177 in
HMVECs (Figure 5A, lane 2, 27216% of lane 1) and
TRLEC-03 (Figure 5B, lane 2, 30039% of lane 1). In
contrast, ATRA did not affect eNOS protein expression
(Figure 5A and 5B, lower blots) as well as eNOS mRNA
expression determined by RT-PCR (data not shown). RAR
agonist Am580 also increased eNOS phosphorylation at
Ser-1177 in HMVECs without changing its protein expres-
sion (Figure 5A, lane 6, 21227% of lane 5). ATRA-induced
eNOS phosphorylation was diminished by cotreatment with
RAR antagonist LE540 (Figure 5A, lane 3, 1515.2% of lane
1) and wortmannin (100 nmol/L) (Figure 5A, lane 4,
987.0% of lane 1). Time course analyses (Figure 5C)
revealed that ATRA increased eNOS phosphorylation after
48 hours (lane 3). ATRA did not increase iNOS protein
expression (data not shown). These data suggest that ATRA
enhances eNOS phosphorylation at Ser-1177, mediated
through RAR and PI3K, later than 48 hours.
Effects of ATRA on Akt Phosphorylation
Akt, a serine/threonine protein kinase that lies downstream
of PI3K and is a major target of PI3K, is known to directly
phosphorylate eNOS at Ser-1177, which results in en-
hancement of eNOS activity and increase of NO produc-
tion from vascular ECs.31,32 We therefore examined in-
volvement of Akt in the ATRA-induced eNOS
phosphorylation (Figure 5D). When TRLEC-03 was trans-
fected with wild-type Akt, ATRA enhanced eNOS phos-
phorylation (lane 2, 39847% of lane 1). However, when
cells were transfected with dominant-negative Akt, ATRA
could not enhance eNOS phosphorylation (lane 3,
17539% of lane 1), indicating involvement of Akt in the
ATRA-induced eNOS phosphorylation. Effects of ATRA
on Akt phosphorylation were next examined. Western
blotting with the use of antibody against phospho-Akt
(Ser-473) or Akt revealed that ATRA significantly in-
creased Akt phosphorylation at Ser-473 in HMVECs
(Figure 6A, lane 2, 30848% of lane 1) and TRLEC-03
(Figure 6A, lane 8, 31343% of lane 7) without changing
its protein expression (Figure 6A, lower blots). ATRA-
induced Akt phosphorylation in both cells was diminished
Figure 2. Effects of dose (A) or exposure time (B) of ATRA on
NO production in TRLEC-03. Cells were incubated with ATRA
for 48 hours at indicated concentrations (A) or incubated at 1
mol/L for indicated times (B). NO production was determined
by DAF-2T fluorescence. Results in A and B represent
meanSEM of 3 independent experiments (n18). In A,
†P0.01, *P0.05 vs 0 mol/L. In B, *P0.01 vs 0 hour.
Figure 3. Effects of specific NO scavenger carboxy-PTIO or NO
synthase inhibitor L-NAME on DAF-2T fluorescence in TRLEC-
03. A, NO imaging of indicating conditions. Cells were incu-
bated with [ATRA()] or without [ATRA()] ATRA (1 mol/L) for
48 hours. PBS (vehicle), 300 mol/L carboxy-PTIO (C-PTIO), or
300 mol/L L-NAME (L-NAME) was added 30 minutes before
DAF-2 DA loading. Results in B represent meanSEM of
DAF-2T fluorescence of 3 independent experiments (n18).
*P0.01 vs lane 1; †P0.01 vs respective vehicle (lane 1 or 4).
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by treatment with wortmannin (100 nmol/L) (Figure 6A,
lanes 4 and 9) and was inhibited by cotreatment with RAR
antagonist LE540 (Figure 6A, lane 3, 13516% of lane 1;
Figure 6B, lane 8). RAR agonist Am580 also increased Akt
phosphorylation at Ser-473 in HMVECs without changing
its protein expression (Figure 6A, lane 6, 23147% of lane
5). Time course analyses (Figure 6B) revealed that ATRA
increased Akt phosphorylation after 48 hours in both cells
(lanes 3 and 7). Moreover, ATRA increased Akt phosphor-
ylation in a concentration-dependent manner (Figure 6C).
These data suggest that ATRA phosphorylates Akt at
Ser-473, mediated through RAR and PI3K, later than 48
hours.
Effects of ATRA on PI3K Activity/Catalytic
Subunit p110 Protein Expression
Effects of ATRA on PI3K activity in TRLEC-03 were next
examined. PI3K activity assay revealed that ATRA markedly
increased PI3K activity after 48 hours (Figure 7A, 46028%
of 0 hour) but not by 24 hours. Because ATRA is known to
induce expression of PI3K catalytic subunit p110 protein
and increase PI3K activity in a neuroblastoma cell line,33 we
next examined effects of ATRA on p110 protein expression
in TRLEC-03. ATRA significantly increased p110 protein
Figure 4. Involvement of RAR and PI3K in ATRA-induced NO
increase in TRLEC-03. Expression of retinoid receptors in
TRLEC-03. Ten micrograms of TRLEC-03 nuclear extracts was
electrophoresed, and Western blotting with the use of antibody
against RAR, ,  (A) or RXR, ,  (B) was performed. C,
Effects of RAR/RXR antagonists on NO increase in TRLEC-03.
RAR antagonist LE540 (1 mol/L) and/or RXR antagonist HX603
(1 mol/L) was coincubated with ATRA (1 mol/L) for 48 hours.
Results represent meanSEM of DAF-2T fluorescence of 3
independent experiments (n18). *P0.01 vs lane 1; †P0.05
and ‡P0.01 vs lane 2. D, Effects of PI3K inhibitor wortmannin
or LY294002 on NO increase in TRLEC-03. Cells were incu-
bated with [ATRA()] or without [ATRA()] ATRA (1 mol/L) for
48 hours. Dimethyl sulfoxide (vehicle), wortmannin (30 nmol/L),
or LY294002 (20 mol/L) was added 30 minutes before DAF-2
DA loading. Results represent meanSEM of DAF-2T fluores-
cence of 3 independent experiments (n18). *P0.01 vs lane 1;
†P0.01 vs lane 2.
Figure 5. Effects of ATRA on eNOS phosphorylation at Ser-1177
in ECs. A and C, Effects of ATRA in HMVECs. In A, cells were
incubated for 48 hours either with ATRA (1 mol/L) (lane 2),
without ATRA (lane 1), with ATRA and LE540 (1 mol/L) (lane 3),
or with ATRA and wortmannin (100 nmol/L, added 30 minutes
before protein extraction) (Wort) (lane 4). HMVECs were also
incubated with (lane 6) or without (lane 5) Am580 (1 mol/L) for
48 hours. *P0.01 vs lane 1; †P0.01 vs lane 2; ‡P0.01 vs
lane 5. In C, cells were treated with ATRA (1 mol/L) for indi-
cated times. B, Effects of ATRA in TRLEC-03. Cells were incu-
bated for 48 hours either with (lane 2) or without (lane 1) ATRA
(1 mol/L). *P0.01 vs lane 1. D, Effects of Akt on ATRA-
induced eNOS phosphorylation. TRLEC-03 transfected either
with wild-type eNOS and wild-type Akt (WT-Akt) (lanes 1 and 2)
or wild-type eNOS and dominant-negative Akt (DN-Akt) (lane 3)
was incubated with (lanes 2 and 3) or without (lane 1) ATRA (1
mol/L) for 48 hours. *P0.01 vs lane 1; †P0.01 vs lane 2. In
A to D, Western blotting was performed with the use of anti-
body against phospho-eNOS (Ser-1177) (upper blots, p-eNOS)
or eNOS (lower blots, eNOS). In A, B, and D, phosphorylation of
eNOS at Ser-1177 was determined by densitometry of
phospho-eNOS or of eNOS (meanSEM; n6).
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expression (Figure 7B, lane 2, 20620% of lane 1), which
was completely inhibited by cotreatment with the RAR
antagonist LE540 (Figure 7B, lane 3, 577.0% of lane 1).
Time course analyses (Figure 7C) revealed that ATRA
increased p110 protein expression after 48 hours. Moreover,
ATRA increased p110 protein expression around 107 and
106 mol/L (Figure 7D), consistent with the ATRA-induced
NO increase. These data suggest that ATRA increases PI3K
catalytic subunit p110 protein expression and PI3K activity,
mediated through RAR, later than 48 hours.
Effects of ATRA on PI3K Catalytic Subunit p110
mRNA Expression
Effects of ATRA on PI3K catalytic subunit p110 mRNA
expression in TRLEC-03 were next examined by real-time
PCR with the use of SYBR Green I. As shown in standard
curves of Figure 7E, the threshold cycle values for the mRNA
of p110 and GAPDH showed good correlation with the
amount of templates in the real-time PCR analyses, indicating
the reliability of the obtained data. As shown in Figure 7F,
ATRA treatment (1 mol/L, 48 hours) significantly increased
p110 mRNA expression [20521% of ATRA()]. To
examine ATRA effects on p110 mRNA stability, we next
treated the cells with actinomycin D for an additional 3 or 6
hours. As shown in Figure 7G, p110 mRNA equally
degraded either in the absence or presence of ATRA. These
data indicate that ATRA induces increase of PI3K catalytic
subunit p110 mRNA expression without affecting its
stability.
Involvement of eNOS Ser-1177 in NO Increase
To examine direct involvement of eNOS Ser-1177 in the
ATRA-induced NO increase, we next transfected either
wild-type eNOS or mutated eNOS with RAR into COS-1
cells and incubated the cells with or without ATRA (1
mol/L) for 48 hours. As shown in Figure 8, ATRA induced
NO increase (lane 2, 20514% of lane 1) in the presence of
wild-type eNOS. In contrast, ATRA could not induce NO
production in the presence of mutated eNOS whose Ser-1177
was substituted to Ala (lanes 3 and 4). These data indicate
direct involvement of eNOS Ser-1177, most likely by its
phosphorylation, in the ATRA-induced NO increase.
Discussion
In the present study we demonstrated increase of NO produc-
tion by ATRA mediated by eNOS phosphorylation through
activation of the PI3K/Akt pathway in vascular ECs. We first
demonstrated ATRA-induced increase of NO production. The
fluorescent NO indicator DAF-2 DA was used to determine
NO production, and its specificity was confirmed by inhibi-
tion of its fluorescence by treatment with either the NOS
inhibitor L-NAME or the specific NO scavenger carboxy-
PTIO. ATRA increased NO production in a concentration-
dependent manner from 107 to 106 mol/L. The physiolog-
ical concentration of basal plasma ATRA is 108 mol/L,
and the pharmacological concentration of plasma ATRA after
oral administration in patients with leukemia or solid tumor
reaches 106 mol/L.34 Therefore, ATRA can induce NO
increase not only at pharmacological concentrations but also
at physiological concentrations. In addition to the increase of
basal NO production, ATRA was also demonstrated to
enhance ACh-induced NO release. Because expression of M3
muscarinic ACh receptor, which is known to mediate ACh
action predominantly in the vasculature,27 has been demon-
strated in both HUVECs and TRLEC-03, the observed
ACh-induced NO release may be mediated through the M3
receptor. Our data are consistent with the previous report
describing improvement of ACh-induced relaxation response
of blood vessel by ATRA treatment.12 Because attenuation of
ACh-induced relaxation response is usually observed under
Figure 6. Effects of ATRA on Akt phosphorylation at Ser-473 in
ECs. A, HMVECs (lanes 1 to 4) or TRLEC-03 (lanes 7 to 9) was
incubated for 48 hours either with ATRA (1 mol/L) (lanes 2 and
8), without ATRA (lanes 1 and 7), with ATRA and LE540 (1
mol/L) (lane 3), or with ATRA and wortmannin (100 nmol/L,
added 30 minutes before protein extraction) (Wort) (lanes 4 and
9). HMVECs were also incubated with (lane 6) or without (lane 5)
Am580 (1 mol/L) for 48 hours. *P0.01 vs lane 1 or 7;
†P0.01 vs lane 2 or 8; ‡P0.01 vs lane 5. B, HMVECs (lanes
1 to 3) or TRLEC-03 (lanes 4 to 8) was incubated with ATRA (1
mol/L) for indicated times. In lane 8, LE540 (1 mol/L) was
coincubated with ATRA. C, TRLEC-03 was incubated for 48
hours with ATRA at indicated concentrations. In A to C, Western
blotting with the use of antibody against phospho-Akt (Ser-473)
(p-Akt) or Akt (Akt) was performed. In A, phosphorylation of Akt
at Ser-473 was determined by densitometry of phospho-Akt or
of Akt (meanSEM; n6).
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endothelial dysfunction, the ATRA effect may be beneficial
for recovery of responsiveness to ACh in cases of endothelial
damage.
We also demonstrated that the ATRA-induced NO increase
was mediated by eNOS phosphorylation at Ser-1177 through
the PI3K/Akt pathway, as previously observed in vascular
endothelial growth factor29 and estradiol.30 Because a previ-
ous study has demonstrated NO increase by ATRA through
alteration of the metabolism of the endogenous NOS inhibitor
ADMA,15 ATRA may affect NO production through a dual
mechanism. The PI3K/Akt pathway is reported to play
important roles in vascular ECs, including cell survival35 and
migration.36 ATRA may therefore be able to affect endothe-
lial function other than eNOS activation through the PI3K/
Akt pathway. Time course analyses demonstrated that NO
increase as well as eNOS phosphorylation was observed later
than 48 hours after ATRA treatment. Consistent with their
time course, Akt phosphorylation, PI3K activity increase, and
PI3K catalytic subunit p110 protein expression were also
observed later than 48 hours after ATRA treatment.
Figure 7. Effects of ATRA on PI3K in TRLEC-03. A, PI3K activity
in TRLEC-03. Cells were incubated with ATRA (1 mol/L) for
indicated times, and their PI3K activity was measured by ELISA.
*P0.01 vs 0 hour. B, Effects of ATRA on PI3K catalytic subunit
p110 protein expression in TRLEC-03. Cells were incubated for
48 hours either with ATRA (1 mol/L) (lane 2), without ATRA
(lane 1), or with ATRA and LE540 (1 mol/L) (lane 3). Results
represent meanSEM (n6). *P0.01 vs lane 1; †P0.01 vs
lane 2. C, Time course analyses of PI3K catalytic subunit p110
protein expression in TRLEC-03. Cells were incubated with
ATRA (1 mol/L) for indicated times. D, Dose-response analyses
Figure 8. Involvement of eNOS Ser-1177 in NO increase.
COS-1 cells were transfected with either wild-type eNOS
(eNOS-WT) or mutated eNOS whose Ser-1177 was substituted
to Ala (eNOS-S1177A) and RAR. Cells were then incubated
with [ATRA()] or without [ATRA()] ATRA (1 mol/L) for 48
hours, and NO production was measured with the use of DAF-
2DA. Results represent meanSEM of 3 independent experi-
ments (n18). *P0.01 vs lane 1.
of PI3K catalytic subunit p110 protein expression in TRLEC-03.
Cells were incubated with ATRA for 48 hours at indicated con-
centrations. In B to D, Western blotting with the use of antibody
against PI3K catalytic subunit p110 protein (p110) was per-
formed. E, Standard curves for real-time PCR analyses of PI3K
catalytic subunit p110 (PI3K p110) and GAPDH mRNAs.
Serial dilutions of templates (40 ng, 10 ng, 4 ng, 1 ng, 400 pg,
and 100 pg) were used for real-time PCR, and obtained thresh-
old cycle (Ct) values of each mRNA were plotted against
amounts of templates. The equations of the lines for each
mRNA were calculated by linear regression analyses. PI3K
p110: y1.221450.43; GAPDH: y0.981731.829. F,
Effects of ATRA on PI3K catalytic subunit p110 mRNA expres-
sion in TRLEC-03 examined by real-time PCR. Cells were incu-
bated for 48 hours either with [ATRA()] or without [ATRA()] 1
mol/L ATRA. Bar graphs represent meanSEM (n6) of p110
mRNA levels normalized by GAPDH mRNA levels. *P0.05 vs
ATRA(). G, Effect of ATRA on PI3K catalytic subunit p110
mRNA stability examined by real-time PCR. TRLEC-03 incu-
bated either with or without 1 mol/L ATRA for 48 hours was
further incubated with actinomycin D (5 g/mL) for an additional
3 or 6 hours. Lines represent meanSEM (n4) of p110
mRNA levels normalized by GAPDH mRNA levels.
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We showed the expression of both retinoid receptors, RAR
and RXR, in vascular ECs. ATRA binds to and activates
RAR. However, ATRA easily converts to 9-cis retinoic acid,
which binds to and activates both RAR and RXR, by
intracellular reciprocal isomerization.37 Therefore, adminis-
tration of ATRA would activate both retinoid receptors. We
thus used receptor-selective antagonists to define the retinoid
receptors involved in the ATRA-induced NO increase. The
RAR antagonist LE540, but not the RXR antagonist HX603,
suppressed ATRA-induced NO increase. Because HX603
concentration (1 mol/L) is enough for inhibiting RXR
agonist-mediated RXR transactivation,18 we speculate that
RXR may not be involved in the NO increase. Furthermore,
ATRA-induced eNOS phosphorylation, Akt phosphorylation,
and PI3K catalytic subunit p110 protein increase were all
inhibited by LE540. Moreover, the RAR agonist Am580 was
shown to induce NO increase, eNOS phosphorylation, and
Akt phosphorylation. This therefore indicates that ATRA-ac-
tivated RAR induces PI3K catalytic subunit p110 protein
expression to increase PI3K activity, resulting in sequential
phosphorylation of Akt and eNOS. Real-time PCR analyses
demonstrated a significant increase of PI3K catalytic subunit
p110 mRNA expression by ATRA, indicating that the
ATRA-induced p110 protein increase was most likely due
to its mRNA increase. The ATRA-induced increase of p110
mRNA expression may possibly be due to RAR-mediated
increase of gene transcription, because p110 mRNA stabil-
ity was not affected by ATRA. Further studies are needed to
examine ATRA/RAR effects on PI3K catalytic subunit
p110 gene transcription by analyzing its promoter activity.
Antiproliferative effects of retinoids, including ATRA,
have recently been reported in VSMCs.2 ATRA inhibits
VSMC proliferation by modulation of cell cycle regulators,38
downregulation of angiotensin II type 1 receptor expres-
sion,4,39 and induction of apoptosis.40 Moreover, ATRA
suppresses neointima formation and restenosis after balloon
injury in vivo.5,6 In contrast to VSMCs, effects of retinoids on
vascular ECs have been less investigated. Our study has
therefore provided a novel action of retinoids on vascular ECs
in terms of improvement of endothelial function through NO
production. Retinoids are thus beneficial for both VSMCs and
vascular ECs against cardiovascular disorders. Recently, new
synthetic retinoids with fewer side effects such as Am80 were
improved and obtained good results in the hematology field.41
Therefore, improvement of novel retinoids may provide novel
therapeutic treatments not only in proliferative vascular
diseases but also in vascular diseases with endothelial
damage.
In conclusion, we have shown that ATRA increases NO
production by eNOS phosphorylation through RAR-mediated
activation of the PI3K/Akt pathway in vascular ECs and
possibly plays a beneficial role in the vascular endothelium.
Retinoids may therefore be candidates for novel therapeutic
agents against vascular disorders with endothelial damage.
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